Trial Profile
Bevacizumab With Pelvic Radiotherapy And Primary Chemotherapy in Patients With Poor-Risk Rectal Cancer: the BRANCH Trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Fluorouracil; Levofolinic acid; Oxaliplatin; Raltitrexed
- Indications Rectal cancer
- Focus Therapeutic Use
- Acronyms BRANCH
- 01 Nov 2019 Status changed from active, no longer recruiting to completed.
- 13 Sep 2017 Planned End Date changed from 1 Mar 2017 to 1 Jul 2018.
- 13 Sep 2017 Planned primary completion date changed from 1 Mar 2016 to 1 Dec 2017.